EP-1222: Lung SBRT with Dynamic Tracking (DT) on the VERO (Brainlab-Mitsubishi) system  by Jimenez, G. et al.
ESTRO 35 2016                                                                                                                                                    S579 
________________________________________________________________________________ 
Conclusion: AHRT is a reasonable alternative to conventional 
fractionated radiotherapy in stage I-II NSCLC without access 
to SABR and in stage III patients unfit for concurrent 
chemotheraphy. In both groups, treatment was well tolerated 
without grade 3 or higher treatment-related toxicity. PS >2 
was an independent risk factor for OS and CSS. 
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Purpose or Objective: Since 2014, the VERO system 
equipped with dynamic tracking DT has been used in our 
center for lung SBRT.The purpose of this work is to compare 
2 compensation techniques for lung SBRT, DT and a method 
based on the definition of an ITV, in terms of PTV volume 
reduction and treatment time. 
 
Material and Methods: The VERO is an O ring system 
equipped with a gimbaled linac allowing pan and tilt 
rotations and with a stereoscopic dual-source kV X-ray 
imaging allowing the guidance of the tracking. A 4DCT is done 
to measure the range of the target movements with the 
breath: if the amplitude is < 7mm, an ITV is determined on 
the MIP images and if it is > 7mm, the DT method is 
preferred. A gold marker (Visicoil, IBA) is then implanted in 
the lesion and a new 4DCT is realized 1 week later. The 
GTVDT is drawn on the exhale phase and the PTVDT is 
defined with a 5mm margin. The dose is prescribed on the 
isodose covering 95 % of the PTV (Monte Carlo): the 
peripheral tumors receive 3x17 Gy, near the thoracic wall 
4x12 Gy and near the mediastin 8x7,5 Gy. The metastatic 
diseases received 5x10 Gy. For DT, treatments are delivered 
with 6-8 no coplanar beams. 
 
Results: 77 patients were treated with lung SBRT, including 
22 patients treated with DT. Among these 22 patients, the 
PTVITV was however estimated: the average size of the 
PTVDT was 28.8cc(6.5 - 14.3 cc) and that of the PTVITV was 
46.4cc(10.4 in 139 cc), so a 40 % reduction of the PTV 
volume. The average session length in DT was 35 min, the 
same as with the ITV method. The breathing rate of the 
patients was often irregular during the session and especially 
compared with the reference 4DCT. It did not affect the 
treatment delivery neither the guidance of the tracking. The 
clinical tolerance during and after the SBRT with tracking was 
excellent: 1 patient that was already treated for interstitial 
pulmonary fibrosis developed symptomatic radiation 
pneumonitis (RP). 5 other patients had radiological RP on the 
CT done during their first 6 months follow up period ; all of 
them received corticosteroid therapy and did not show any 
symptoms. There was no chest wall toxicity. Over a 16 
months follow-up,1 patient did not benefit from treatment 
with DT SBRT and had a progressive disease. 
 
Conclusion: With a 40% reduction of the PTV, this DT 
technique makes it easy to monitor all the patients breathing 
motion, including very irregular rates, in a treatment time 
equivalent to more classical techniques based on the ITV. 
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Purpose or Objective: Local failure in lung cancer is 
associated with extremely poor survival. This study tested 
whether the pattern of failure is associated with the most 
PET avid volume in the pre-therapeutic PET/CT scan. 
 
Material and Methods: Patients with inoperable NSCLC 
treated in our department between 2008 and 2010 were 
reviewed. Forty patients, who received radiotherapy (RT) for 
NSCLC and had an accessible pre-therapeutic FDG PET/CT 
scanning, were included. Fifteen of the patients developed 
local failure as the first event. Patient and tumour 
characteristics for patients with recurrences are presented in 
Table 1. The peak SUV area in the pre-therapeutic PET/CT 
scan in both tumor and lymph nodes were identified by an 
experienced nuclear physician who delineated the volume 
encompassing 50% of the maximum SUV (SUVmax50) in all 
fifteen patients. All patients were followed by CT scans every 
third month. The CT scans which showed recurrences (rCT) 
were imported to the Eclipse treatment planning system 
(Varian MS) and the recurrence gross tumor volume(s) (rGTV) 
was delineated. A rigid registration between pre-therapeutic 
PET/CT and treatment planning CT (pCT) was performed 
using a soft tissue match on the tumor or the lymph nodes in 
SmartAdapt (Varian MS). The SUVmax50 volumes were copied 
to pCT using the rigid registration. The rCT with the defined 
rGTV were also fused with the pCT using a rigid registration 
based on normal tissue nearby the rGTV but excluding the 
rGTV. The vertebral column or the aortic arch was found to 
be preferable. Two radiation oncologists assessed the rigid 
registration between pCT and rCT. 
 
Results: The patients received conventionally fractionated 
RT with a total dose of 60-66 Gy. Planning target volumes 
(PTV) ranged from 169 cm3 to 1065 cm3 (mean = 678 cm3). 
Median time to local progression was seven months (95% CI 5-
9 months). In twelve patients, the recurrences of the primary 
tumor appeared inside the PTV. In three cases, the 
recurrences were both inside and outside the PTV. These 
three recurrences outside the PTV appeared in mediastinal 
lymph node region. The rGTV overlapped with the pre-
therapeutic PET sub-volumes in twelve patients (Figure 1). In 
one case, rGTV was near the PET sub-volume area without 
overlapping. In one patient, part of the target was missed 
because an atelectasis obscured the PET/CT signal and made 
the delineation of GTV less optimal. 
 
 
